Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | CES1 | P23141 | 4/20 | 0.37 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408240 | 0.92 | CES2 (0.42) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL5403727 | 0.83 | CES2 (0.43) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL5410812 | 0.82 | TDP1 (0.39) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL5465569 | 0.77 | MEN1 (0.37) | TDP1MEN1KMT2ALMNATSHR | |
| SCHEMBL5407675 | 0.76 | CES2 (0.41) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL6266086 | 0.75 | CES2 (0.47) | CES2CYP2C9GMNNTP53POLB | |
| Hydrochloric Acid SCHEMBL5403361 | 0.74 | CES2 (0.46) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL5407644 | 0.74 | CES2 (0.38) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL5421564 | 0.73 | CES2 (0.49) | CES2CYP2C9GMNNTP53POLB | |
| SCHEMBL5408248 | 0.72 | MEN1 (0.41) | HSD17B10TDP1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253296-B2 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2007-08-07 | — | — | US | disclosed |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | disclosed |
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2006-03-30 | — | — | US | disclosed |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | GENTIF (FR) | 2006-02-16 | — | — | US | disclosed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | disclosed |
| EP-1594486-A2 | USES OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME | Genfit (FR) | 2005-11-16 | — | — | EP | disclosed |
| EP-1592660-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | Genfit (FR) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004073593-A2 | USE OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME FOR DIFFERENT THERAPEUTIC APPLICATIONS | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074239-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | AASDHPPT, ABAT, AADAC | CES2 944/4885CYP2C9 3797/4885GMNN 2989/4885 |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | ASS1, SMURF1, SMURF2 | CES2 1728/4885CYP2C9 2833/4885GMNN 2879/4885 |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | AGPAT5, HAGH, AGPAT2 | CES2 1234/4885CYP2C9 3639/4885GMNN 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.